3 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 58, n° 3
pages 403-406 (mars 2008)
Doi : 10.1016/j.jaad.2007.08.014
accepted : 9 August 2007
Leflunomide as adjuvant treatment of dermatomyositis

J. Scott Boswell, MD, Melissa I. Costner, MD
Department of Dermatology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 

Reprint requests: Melissa I. Costner, MD, North Dallas Dermatology, 9301 N Central Expressway, Suite 180, North Central Medical Plaza Tower II, Dallas, TX 75231.

We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis. In our patients, leflunomide proved both safe and effective as adjuvant therapy in treating dermatomyositis.

The full text of this article is available in PDF format.

 Funding sources: None.
 Conflicts of interest: None declared.

© 2008  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline